{"title":"SAMHSA awards almost $250 million for SUD and mental health","authors":"Alison Knopf","doi":"10.1002/adaw.35068","DOIUrl":"https://doi.org/10.1002/adaw.35068","url":null,"abstract":"<p>Last week the Substance Abuse and Mental Health Services Administration (SAMHSA) awarded almost $250 million for services to treat substance use disorder (SUD), prevent death from overdose, and provide mental health treatment. “These grants will help communities reach people at critical moments, such as when a child is struggling with trauma, when someone is ready to seek treatment for opioid use disorder, when a first responder arrives at the scene of an overdose, or when a person in recovery is working to rebuild their life,” said SAMHSA Principal Deputy Assistant Secretary Christopher D. Carroll in announcing the grants September 25. “With more tools and resources, communities can better connect people to care when they need it and support them on the path to recovery.” The awards, which are authorized by law, include.</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"38 38","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149099299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Coming Up…","authors":"","doi":"10.1002/adaw.35069","DOIUrl":"https://doi.org/10.1002/adaw.35069","url":null,"abstract":"<p>The <b>InUnity Alliance</b> annual conference will be held in Saratoga Springs, New York <b>October 13-15</b>. For more information, go to https://www.recoveryanswers.org/coarsconference/.</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"38 38","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149099342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Coming Up…","authors":"","doi":"10.1002/adaw.35061","DOIUrl":"https://doi.org/10.1002/adaw.35061","url":null,"abstract":"<p><b>Faces & Voices of Recovery</b> will hold a virtual recovery leadership summit <b>October 6-8</b>. For more information, go to https://rls.facesandvoicesofrecovery.org/</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"38 37","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149027724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Bill attacking methadone flexibilities appears dead after field pushback","authors":"Alison Knopf","doi":"10.1002/adaw.35054","DOIUrl":"https://doi.org/10.1002/adaw.35054","url":null,"abstract":"<p>Last year, Rep. Erin Houchin (R-Indiana) introduced a bill which would undo the flexibilities put into methadone treatment policies in opioid treatment programs (OTPs) by the federal government in 2024 (see <i>ADAW</i> https://onlinelibrary.wiley.com/doi/10.1002/adaw.34023). These flexibilities included more liberal take-home policies, which were based on experience during the COVID 2019 pandemic, when such policies were allowed to avoid the possible transmission of the virus by patients going to OTPs to pick up medication. The experience was positive: there was no increase in adverse events such as diversion or deaths due to the more liberal take-homes. In fact, liberalizing take-homes and other flexibility rules for OTPs are seen as tools to fight the fentanyl epidemic, which is still killing tk people a year in the United States.</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"38 37","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149027769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comments on methadone take-home timing study","authors":"Alison Knopf","doi":"10.1002/adaw.35056","DOIUrl":"https://doi.org/10.1002/adaw.35056","url":null,"abstract":"<p>Last week we wrote about a study and accompanying commentary published in <i>JAMA Internal Medicine</i> that found methadone take-homes can be given too early — namely, in the first four weeks of treatment (see https://onlinelibrary.wiley.com/doi/10.1002/adaw.35049). The study, “Timing of Initiation of Methadone Take-Home Dosing,” by Belal Hossain, and the commentary on it, “Initiation of Take-Home Medication Dosing and Methadone Maintenance Treatment Effectiveness” by Paul J. Joudrey, M.D., supported methadone take-homes in general. Joudrey, who wrote the commentary, has been a particular advocate of “liberating methadone” from U.S. opioid treatment programs (OTPs), allowing physicians to prescribe and pharmacies to dispense it. The study itself was conducted in Canada, where there are no OTPs and methadone is dispensed by pharmacies, without the wraparound services of OTPs.</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"38 37","pages":"3-4"},"PeriodicalIF":0.0,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149027766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Partners join forces to spur translation of research to service","authors":"Gary Enos","doi":"10.1002/adaw.35055","DOIUrl":"https://doi.org/10.1002/adaw.35055","url":null,"abstract":"<p>The importance of closing the chasm between scientific discovery in addiction and its practical application lies at the heart of a newly formed partnership agreement between the Rutgers Addiction Research Center and Partnership to End Addiction. The two entities expect to pursue numerous approaches toward achieving their central goal, from joint research projects to workforce training opportunities to public awareness efforts.</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"38 37","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149027770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Gary Enos, longtime contributor to ADAW, retiring","authors":"Alison Knopf","doi":"10.1002/adaw.35060","DOIUrl":"https://doi.org/10.1002/adaw.35060","url":null,"abstract":"<p>Many <i>ADAW</i> readers know Gary, contributing editor to <i>ADAW</i>, because he has interviewed them over the years. All <i>ADAW</i> readers have known him because they read him every week! A professional journalist, with a reporter background, Enos has been writing the page 1 bottom lead for <i>ADAW</i> — forever. At least, that's how it seems to me, the editor, who will miss him immensely.</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"38 37","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149027723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Study: Barriers impede buprenorphine telehealth for pregnant and postpartum women","authors":"Alison Knopf","doi":"10.1002/adaw.35058","DOIUrl":"https://doi.org/10.1002/adaw.35058","url":null,"abstract":"<p>Pregnant and postpartum women with opioid use disorder (OUD) have a dearth of telehealth treatment for buprenorphine, not because the medication isn't safe for them or because it's not available, but because of other barriers, according to a viewpoint published online September 21 in <i>JAMA Internal Medicine</i>. There is widespread availability of buprenorphine via telehealth due to recent expansion of this modality, but it's not available to pregnant and postpartum women in many states, according to the authors of “Buprenorphine via Telehealth—Closing the Gap for Pregnant and Postpartum Women With Opioid Use Disorder.” The study, by Rachel K. Landis, PhD, MPP, and colleagues, noted that states have different policies about prescribing and utilization. For example, some states allow only in-person prescribing of all controlled substances, including buprenorphine. Others allow only certain clinicians to use telehealth for controlled substances. In addition, states have different requirements for insurance coverage. Medicaid patients face other barriers to telehealth buprenorphine.</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"38 37","pages":"6-7"},"PeriodicalIF":0.0,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149027772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"In Case You Haven't Heard…","authors":"","doi":"10.1002/adaw.35062","DOIUrl":"https://doi.org/10.1002/adaw.35062","url":null,"abstract":"<p>Actress Hayden Panettiere's death was due to an unintentional overdose involving illicit fentanyl, according to the coroner's report released last week. Most likely, the death of Cindy Crawford's son Presley Gerber last week was as well. These two celebrities, famous, with plenty of money, were not able to avoid addiction, because addiction doesn't care who you are. Gerber, who shared his stories of mental and addiction problems openly, was in a rehab facility — the last of many he entered — when he overdosed. In fact, it was his first night there. We can share sorrow and compassion for the families of these young people. But that sorrow and compassion have to be there for everyone, not just the famous people — even if the famous ones are those who finally make the nation wake up about the need for treatment. Unlike other addictions, opioid addiction has proven treatments: methadone, buprenorphine and naltrexone. Why aren't these used more? The pages of <i>ADAW</i> are full of articles about stigma, insurance barriers and funding problems. Meanwhile, reports that Panettiere “secretly” entered a treatment program just before she died raise more questions than answers about how this country views addiction. Programs that combine residential treatment with buprenorphine have proven successful. Why aren't there more of these programs? So many questions, but so few answers.</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"38 37","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149027768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"‘What do you think?’","authors":"Rob Kent Esq.","doi":"10.1002/adaw.35057","DOIUrl":"https://doi.org/10.1002/adaw.35057","url":null,"abstract":"<p>There is a similarity in successful approaches to how we advocate for policy changes and how we help those with addictions improve their health. I have found success in advocacy when I reach the point where policymakers are asking me for my thoughts. I have found far less success when I offer them my unsolicited policy advice. When you take the latter approach, you are assuming that they want to hear what you have to say. Conversely, when they ask for your thoughts, they are open to considering your suggested approach.</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"38 37","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149027771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
